Over the last few years, treatment principles have been changed towards more targeted therapy for many B-cell lymphoma subtypes and in chronic lymphocytic leukemia (CLL). Immunotherapeutic modalities, namely monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T (CAR-T) cell therapy, commonly use B-cell-associated antigens (CD19, CD20, CD22, and CD79b) as one of their targets. T-cell engagers (TCEs), a subclass of bsAbs, work on a similar mechanism as CAR-T cell therapy without the need of previous T-cell manipulation. Currently, several anti-CD20xCD3 TCEs have demonstrated promising efficacy across different lymphoma subtypes with slightly better outcomes in the indolent subset. Anti-CD19xCD3 TCEs are being developed as well but only blinatumomab has been evaluated in clinical trials yet. The results are not so impressive as those with anti-CD19 CAR-T cell therapy. Antibody-drug conjugates targeting different B-cell antigens (CD30, CD79b, CD19) seem to be effective in combination with mAbs, standard chemoimmunotherapy, or immune checkpoint inhibitors. Further investigation will show whether immunotherapy alone or in combinatory regimens has potential to replace chemotherapeutic agents from the first line treatment.

Department of Haematooncology University Hospital Ostrava 708 52 Ostrava Czech Republic

Faculty of Medicine University of Ostrava 708 52 Ostrava Czech Republic

Zobrazit více v PubMed

Jelinek T., Mihalyova J., Kascak M., Duras J., Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: Update 2017. Immunology. 2017;152:357–371. doi: 10.1111/imm.12788. PubMed DOI PMC

Piro L.D., White C.A., Grillo-López A.J., Janakiraman N., Saven A., Beck T.M., Varns C., Shuey S., Czuczman M., Lynch J.W., et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann. Oncol. 1999;10:655–661. doi: 10.1023/A:1008389119525. PubMed DOI

Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. PubMed DOI PMC

Wong R., Pepper C., Brennan P., Nagorsen D., Man S., Fegan C. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica. 2013;98:1930–1938. doi: 10.3324/haematol.2012.082248. PubMed DOI PMC

Seegmiller A.C., Hsi E.D., Craig F.E. The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms. Cytometry B Clin. Cytom. 2019;96:20–29. doi: 10.1002/cyto.b.21756. PubMed DOI

Theocharopoulos C., Lialios P.-P., Gogas H., Ziogas D.C. An overview of antibody–drug conjugates in oncological practice. Ther. Adv. Med. Oncol. 2020;12:1758835920962997. doi: 10.1177/1758835920962997. PubMed DOI PMC

Yu B., Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J. Hematol. Oncol.J. Hematol. Oncol. 2019;12:94. doi: 10.1186/s13045-019-0786-6. PubMed DOI PMC

Zhao P., Zhang Y., Li W., Jeanty C., Xiang G., Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm. Sin. B. 2020;10:1589–1600. doi: 10.1016/j.apsb.2020.04.012. PubMed DOI PMC

Demel I., Bago J.R., Hajek R., Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: Update 2021. Br. J. Haematol. 2021;193:705–722. doi: 10.1111/bjh.17235. PubMed DOI

Matsuda Y., Mendelsohn B.A. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opin. Biol. Ther. 2020;21:963–975. doi: 10.1080/14712598.2021.1846714. PubMed DOI

Torre B.G., Albericio F. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Mol. Basel Switz. 2021;26:627. doi: 10.3390/molecules26030627. PubMed DOI PMC

Sehn L.H., Herrera A.F., Flowers C.R., Kamdar M.K., McMillan A., Hertzberg M., Assouline S., Kim T.M., Kim W.S., Ozcan M., et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020;38:155–165. doi: 10.1200/JCO.19.00172. PubMed DOI PMC

Tilly H., Morschhauser F., Bartlett N.L., Mehta A., Salles G., Haioun C., Munoz J., Chen A.I., Kolibaba K., Lu D., et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: An open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019;20:998–1010. doi: 10.1016/S1470-2045(19)30091-9. PubMed DOI

Magid Diefenbach C.S., Abrisqueta P., Gonzalez-Barca E., Panizo C., Arguinano Perez J.M., Miall F., Bastos-Oreiro M., Lopez-Guillermo A., Banerjee L., McMillan A., et al. Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial. J. Clin. Oncol. 2021;39:7512. doi: 10.1200/JCO.2021.39.15_suppl.7512. DOI

Diefenbach C., Kahl B., Banerjee L., McMillan A., Miall F., Briones J., Cordoba R., Hirata J., Chang Y., Musick L., et al. Phase Ib/II Trial of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population; Proceedings of the BSH 2020 VIRTUAL; Virtual. 9–14 November 2020; p. PO-106-A.

Zinzani P.L., Caimi P.F., Carlo-Stella C., Ai W., Alderuccio J.P., Ardeshna K.M., Hess B., Kahl B.S., Radford J., Solh M., et al. Lotis 2 follow-up analysis: Updated results from a phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large b-cell lymphoma. Hematol. Oncol. 2021;39:hon.89_2880. doi: 10.1002/hon.89_2880. DOI

Hamadani M., Radford J., Carlo-Stella C., Caimi P.F., Reid E., O’Connor O.A., Feingold J.M., Ardeshna K.M., Townsend W., Solh M., et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137:2634–2645. doi: 10.1182/blood.2020007512. PubMed DOI PMC

Depaus J., Wagner-Johnston N., Zinzani P.L., Phillips T.J., Maly J., Ferrari S., Bachy E., Bryan L.J., Delwail V., Janakiram M., et al. Clinical activity of loncastuximab tesirine plus ibrutinib in non-hodgkin lymphoma: Updated lotis 3 phase 1 results. Hematol. Oncol. 2021;39:S2. doi: 10.1002/hon.150_2880. DOI

Svoboda J., Bair S.M., Landsburg D.J., Nasta S.D., Nagle S.J., Barta S.K., Khan N., Filicko-O’Hara J., Gaballa S., Strelec L., et al. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. Haematologica. 2020;106:1705. doi: 10.3324/haematol.2019.238675. PubMed DOI PMC

Schuster S.J., Bartlett N.L., Assouline S., Yoon S.-S., Bosch F., Sehn L.H., Cheah C.Y., Shadman M., Gregory G.P., Ku M., et al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood. 2019;134:6. doi: 10.1182/blood-2019-123742. PubMed DOI

Matasar M., Chan Y.C., Yoon D.H., Elizabeth B.L. Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. ASH Publishing; Ashcroft, BC, Canada: 2020.

Olszewski A., Abraham A., Babu S., Horowitz N. Mosunetuzumab (mosun) monotherapy for elderly/unfit patients (pts) with first-line diffuse large b-cell lymphoma (dlbcl) continues to show promising safety and efficacy with durable complete responses. HemaSphere. 2021;5:e566. doi: 10.1097/HS9.0000000000000566. DOI

Ghosh N., Diefenbach C., Chavez J. Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab (M) with Polatuzumab Vedotin (Pola) in Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (B-NHL) [(accessed on 20 June 2021)]. Available online: https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324630/nilanjan.ghosh.promising.tolerability.and.efficacy.results.from.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dmosunetuzumab.

Hutchings M., Morschhauser F., Iacoboni G., Carlo-Stella C., Offner F.C., Sureda A., Salles G., Martínez-Lopez J., Crump M., Thomas D.N., et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J. Clin. Oncol. 2021;39:1959–1970. doi: 10.1200/JCO.20.03175. PubMed DOI PMC

Morschhauser F., Carlo-Stella C., Offner F., Salles G.A., Hutchings M., Iacoboni G., Sureda A., Crump M., Martinez-Lopez J., Thomas D., et al. Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. Blood. 2019;134:1584. doi: 10.1182/blood-2019-123949. DOI

Mous R., Lugtenburg P., Hutchings M., Roost Clausen M. Subcutaneous Epcoritamab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Safety Profile and Anti-Tumor Activity. [(accessed on 26 June 2021)]. Available online: https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325259/rogier.mous.subcutaneous.epcoritamab.in.patients.with.relapsed.refractory.html?f=listing=0*browseby=8*sortby=1*search=epcoritamab.

Bannerji R., Allan J.N., Arnason J.E., Brown J.R., Advani R.H., Barnes J.A., Ansell S.M., O’Brien S.M., Chavez J., Duell J., et al. Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL) Blood. 2019;134:762. doi: 10.1182/blood-2019-122451. DOI

Herrera A.F., Molina A. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies. Clin. Lymphoma Myeloma Leuk. 2018;18:452–468.e4. doi: 10.1016/j.clml.2018.05.006. PubMed DOI

Deeks E.D. Polatuzumab Vedotin: First Global Approval. Drugs. 2019;79:1467–1475. doi: 10.1007/s40265-019-01175-0. PubMed DOI PMC

Lu T., Gibiansky L., Li X., Li C., Shi R., Agarwal P., Hirata J., Miles D., Chanu P., Girish S., et al. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leuk. Lymphoma. 2020;61:2905–2914. doi: 10.1080/10428194.2020.1795154. PubMed DOI

Burke J.M., Morschhauser F., Andorsky D., Lee C., Sharman J.P. Antibody-drug conjugates for previously treated aggressive lymphomas: Focus on polatuzumab vedotin. Expert Rev. Clin. Pharmacol. 2020;13:1073–1083. doi: 10.1080/17512433.2020.1826303. PubMed DOI

Amin D., Bannerji R., Mali R.S., Oeh J., Lin E., Zindal A., Go M., Yu S.-F., Krem M., Arthur C., et al. Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study; Proceedings of the AACR Annual Meeting 2020; Philadelphia, PA, USA. 22–24 June 2020; p. CT133.

Bannerji R., Yuen S., Phillips T.J., Arthur C., Isufi I., Marlton P., Seymour J.F., Corradini P., Molinari A., Gritti G., et al. Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial. J. Clin. Oncol. 2021;39:7534. doi: 10.1200/JCO.2021.39.15_suppl.7534. DOI

Lee A. Loncastuximab Tesirine: First Approval. Drugs. 2021;81:1229–1233. doi: 10.1007/s40265-021-01550-w. PubMed DOI

Carlo-Stella C., Linhares Y., Gandhi M.D., Chung M., Adamis H., Ungar D., Hamadani M. phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory diffuse large b-cell lymphoma—Lotis-5. Hematol. Oncol. 2021;39:hon.163_2880. doi: 10.1002/hon.163_2880. DOI

Carlo-Stella C., Depaus J., Hess B.T., Kingsley E., Zinzani P.L., Ungar D., Dai V., Wang L., Ardeshna K.M. A phase 2 randomized study of loncastuximab tesirine (lonca) versus (vs) idelalisib in patients (pts) with relapsed or refractory (r/r) follicular lymphoma (fl)—Lotis-6. Hematol. Oncol. 2021;39:hon.176_2880. doi: 10.1002/hon.176_2880. DOI

Richardson N.C., Kasamon Y.L., Chen H., de Claro R.A., Ye J., Blumenthal G.M., Farrell A.T., Pazdur R. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. Oncologist. 2019;24:e180–e187. doi: 10.1634/theoncologist.2019-0098. PubMed DOI PMC

Shea L., Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr. Hematol. Malig. Rep. 2020;15:9–19. doi: 10.1007/s11899-020-00561-w. PubMed DOI

Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., Ramchandren R., Bartlett N.L., Cheson B.D., de Vos S., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2012;30:2183–2189. doi: 10.1200/JCO.2011.38.0410. PubMed DOI PMC

Prince H.M., Kim Y.H., Horwitz S.M., Dummer R., Scarisbrick J., Quaglino P., Zinzani P.L., Wolter P., Sanches J.A., Ortiz-Romero P.L., et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial. Lancet Lond. Engl. 2017;390:555–566. doi: 10.1016/S0140-6736(17)31266-7. PubMed DOI

Horwitz S., O’Connor O.A., Pro B., Illidge T., Fanale M., Advani R., Bartlett N.L., Christensen J.H., Morschhauser F., Domingo-Domenech E., et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial. Lancet Lond. Engl. 2019;393:229–240. doi: 10.1016/S0140-6736(18)32984-2. PubMed DOI PMC

Choi Y., Diefenbach C.S. Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma. Curr. Oncol. Rep. 2020;22:6. doi: 10.1007/s11912-020-0866-3. PubMed DOI

Zinzani P.L., Pellegrini C., Chiappella A., Di Rocco A., Salvi F., Cabras M.G., Argnani L., Stefoni V. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: Results from a phase 2 clinical trial. Blood. 2017;129:2328–2330. doi: 10.1182/blood-2017-01-764258. PubMed DOI

Zinzani P.L., Santoro A., Gritti G., Brice P., Barr P.M., Kuruvilla J., Cunningham D., Kline J., Johnson N.A., Mehta-Shah N., et al. Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large b-cell lymphoma: Extended follow-up from the phase 2 checkmate 436 stUDY. Hematol. Oncol. 2021;39:hon.51_2879. doi: 10.1002/hon.51_2879. PubMed DOI

Bartlett N.L., Yasenchak C.A., Ashraf K.K., Harwin W.N., Sims R.B., Nowakowski G.S. Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) (trial in progress) Hematol. Oncol. 2021;39:hon.166_2880. doi: 10.1002/hon.166_2880. DOI

Stathis A., Flinn I.W., Madan S., Maddocks K., Freedman A., Weitman S., Zucca E., Munteanu M.C., Lia Palomba M. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A dose-escalation, phase I study. Invest. N. Drugs. 2018;36:869–876. doi: 10.1007/s10637-018-0570-4. PubMed DOI PMC

Szczepański T., van der Velden V.H.J., van Dongen J.J.M. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin. Chem. Lab. Med. 2006;44:775–796. doi: 10.1515/CCLM.2006.146. PubMed DOI

Levy M.Y., Grudeva-Popova Z., Trneny M., Jurczak W., Pylypenko H., Jagadeesh D., Andre M., Nasta S., Rechavi-Robinson D., Toffanin S., et al. Safety and efficacy of cd37-targeting naratuximab emtansine plus rituximab in diffuse large b-cell lymphoma and other non-hodgkin’s b-cell lymphomas—A phase 2 study. Hematol. Oncol. 2021;39:hon.156_2880. doi: 10.1002/hon.156_2880. DOI

Morschhauser F., Flinn I.W., Advani R., Sehn L.H., Diefenbach C., Kolibaba K., Press O.W., Salles G., Tilly H., Chen A.I., et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: Final results from a phase 2 randomised study (ROMULUS) Lancet Haematol. 2019;6:e254–e265. doi: 10.1016/S2352-3026(19)30026-2. PubMed DOI

Collins G., Horwitz S., Davies A., Karnad A., Samaniego F., Spira A., Fields P., Menne T., Boni J., Cruz H., et al. Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma. Blood. 2018;132:1658. doi: 10.1182/blood-2018-99-115986. DOI

Zinzani P.L., Carlo-Stella C., Hamadani M., Herrera A.F., Ansell S.M., Radford J., Maddocks K., Kline J., Savage K.J., Bartlett N.L., et al. Camidanlumab tesirine efficacy and safety in an open-label, multicenter, phase 2 study of patients (pts) with relapsed or refractory classical hodgkin lymphoma (r/r chl) Hematol. Oncol. 2021;39:hon.75_2879. doi: 10.1002/hon.75_2879. DOI

Coiffier B., Thieblemont C., de Guibert S., Dupuis J., Ribrag V., Bouabdallah R., Morschhauser F., Navarro R., Le Gouill S., Haioun C., et al. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Br. J. Haematol. 2016;173:722–730. doi: 10.1111/bjh.13992. PubMed DOI

Trnĕný M., Verhoef G., Dyer M.J., Ben Yehuda D., Patti C., Canales M., Lopez A., Awan F.T., Montgomery P.G., Janikova A., et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103:1351–1358. doi: 10.3324/haematol.2017.168401. PubMed DOI PMC

Tannir N.M., Forero-Torres A., Ramchandren R., Pal S.K., Ansell S.M., Infante J.R., de Vos S., Hamlin P.A., Kim S.K., Whiting N.C., et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest. N. Drugs. 2014;32:1246–1257. doi: 10.1007/s10637-014-0151-0. PubMed DOI

Owonikoko T.K., Hussain A., Stadler W.M., Smith D.C., Kluger H., Molina A.M., Gulati P., Shah A., Ahlers C.M., Cardarelli P.M., et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother. Pharmacol. 2016;77:155–162. doi: 10.1007/s00280-015-2909-2. PubMed DOI

Phillips T., Barr P.M., Park S.I., Kolibaba K., Caimi P.F., Chhabra S., Kingsley E.C., Boyd T., Chen R., Carret A.-S., et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest. N. Drugs. 2019;37:297–306. doi: 10.1007/s10637-018-0655-0. PubMed DOI PMC

Kontermann R.E., Brinkmann U. Bispecific antibodies. Drug Discov. Today. 2015;20:838–847. doi: 10.1016/j.drudis.2015.02.008. PubMed DOI

Klinger M., Brandl C., Zugmaier G., Hijazi Y., Bargou R.C., Topp M.S., Gökbuget N., Neumann S., Goebeler M., Viardot A., et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226–6233. doi: 10.1182/blood-2012-01-400515. PubMed DOI

Topp M.S., Gökbuget N., Stein A.S., Zugmaier G., O’Brien S., Bargou R.C., Dombret H., Fielding A.K., Heffner L., Larson R.A., et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66. doi: 10.1016/S1470-2045(14)71170-2. PubMed DOI

Dreier T., Lorenczewski G., Brandl C., Hoffmann P., Syring U., Hanakam F., Kufer P., Riethmuller G., Bargou R., Baeuerle P.A. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer. 2002;100:690–697. doi: 10.1002/ijc.10557. PubMed DOI

Hoffmann P., Hofmeister R., Brischwein K., Brandl C., Crommer S., Bargou R., Itin C., Prang N., Baeuerle P.A. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer. 2005;115:98–104. doi: 10.1002/ijc.20908. PubMed DOI

Offner S., Hofmeister R., Romaniuk A., Kufer P., Baeuerle P.A. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol. Immunol. 2006;43:763–771. doi: 10.1016/j.molimm.2005.03.007. PubMed DOI

Dahlén E., Veitonmäki N., Norlén P. Bispecific antibodies in cancer immunotherapy. Ther. Adv. Vaccines Immunother. 2018;6:3–17. doi: 10.1177/2515135518763280. PubMed DOI PMC

LaMotte-Mohs R., Shah K., Smith D., Gorlatov S., Ciccarone V., Tamura J., Li H., Rillema J., Licea M., He L., et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Res. 2016;76:3217. doi: 10.1158/1538-7445.AM2016-3217. DOI

Assouline S., Kim W.S., Sehn L.H., Elizabeth B.L. Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. ASH Publishing; Ashcroft, BC, Canada: 2020.

Christian W.S., Bartlett N.L., Loretta N., Franck M. A Phase iii trial (go42909) evaluating mosunetuzumab in combination with lenalidomide (m-len) versus rituximab-lenalidomide (r-len) in patients with relapsed/refractory (r/r) follicular lymphoma (FL) HemaSphere. 2021;5:e566. doi: 10.1097/HS9.0000000000000566. DOI

Dickinson M.J., Morschhauser F., Iacoboni G., Hutchings M. CD20-TCB in Relapsed or Refractory Non-Hodgkin Lymphoma: Durable Complete Responses and Manageable Safety Ob-served at Clinically Relevant Doses in Phase I Dose Escalation. [(accessed on 28 March 2021)]. Available online: https://library.ehaweb.org/eha/2020/eha25th/293690/michael.j.dickinson.cd20-tcb.in.relapsed.or.refractory.non-hodgkin.lymphoma.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Drg6026.

Gramer M.J., van den Bremer E.T.J., van Kampen M.D., Kundu A., Kopfmann P., Etter E., Stinehelfer D., Long J., Lannom T., Noordergraaf E.H., et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches. mAbs. 2013;5:962–973. doi: 10.4161/mabs.26233. PubMed DOI PMC

Hutchings M., Johnson P., Mous R., Lugtenburg P. SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: DOSE-ESCALATION DATA FROM A PHASE 1/2 TRIAL. [(accessed on 10 April 2021)]. Available online: https://library.ehaweb.org/eha/2020/eha25th/293707/martin.hutchings.subcutaneous.epcoritamab.28gen3013.cd3xcd2029.in.patients.with.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Depcoritamab.

Kim T.M., Alonso A., Prince M., Taszner M., Seog K.W. A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. ASH Publishing; Ashcroft, BC, Canada: 2020.

Patel K., Michot J.-M., Chanan-Khan A.A., Salles G.A., Cartron G., Peyrade F., Bouabdallah R., Reid E.G., Thomas S.K., Wierda W.G., et al. Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia. Blood. 2019;134:4079. doi: 10.1182/blood-2019-128564. DOI

Budde E., Gopal A.K., Ian W.F., Armand P. Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies. ASH Publishing; Ashcroft, BC, Canada: 2020.

Viardot A., Goebeler M.-E., Hess G., Neumann S., Pfreundschuh M., Adrian N., Zettl F., Libicher M., Sayehli C., Stieglmaier J., et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–1416. doi: 10.1182/blood-2015-06-651380. PubMed DOI PMC

Viardot A., Goebeler M., Noppeney R., Krause S.W., Kallert S., Ferstl B., Mackensen A., Rupertus K., Soekler M., Kanz L., et al. Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma. Blood. 2011;118:1637. doi: 10.1182/blood.V118.21.1637.1637. DOI

Dufner V., Sayehli C.M., Chatterjee M., Hummel H.D., Gelbrich G., Bargou R.C., Goebeler M.-E. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3:2491–2498. doi: 10.1182/bloodadvances.2019000025. PubMed DOI PMC

Coyle L., Morley N.J., Rambaldi A., Mason K.D., Verhoef G., Furness C.L., Zhang A., Jung A.S., Cohan D., Franklin J.L. Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. ASH Publishing; Ashcroft, BC, Canada: 2020. PubMed

Poh C., Frankel P., Ruel C., Abedi M., Schwab E., Costello C.L., Zain J., Budde L.E., William B.M., Foss F.M., et al. Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin’s Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 2019;134:760. doi: 10.1182/blood-2019-124254. DOI

Ghobadi A., Rettig M.P., Cashen A.F., John F. DiPersio Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large, B. Cell Lymphoma. ASH Publishing; Ashcroft, BC, Canada: 2020.

Katz D.A., Chu M.P., David K.A., Thieblemont C., Morley N.J., Khan S.S., Chen Y., Kalabus J., Morris J., Anderson A., et al. Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma. Blood. 2019;134:4077. doi: 10.1182/blood-2019-121708. DOI

Webster J., Ambinder R.F., Jones R.J., Wagner-Johnston N.D., Prince G.T., Shedeck A., Blackford A., Luznik L., Gojo I. A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (allo-BMT) Remission Maintenance. Blood. 2019;134:778. doi: 10.1182/blood-2019-128255. DOI

Malik-Chaudhry H.K., Prabhakar K., Ugamraj H.S., Boudreau A.A., Buelow B., Dang K., Davison L.M., Harris K.E., Jorgensen B., Ogana H., et al. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL. mAbs. 2021;13:1890411. doi: 10.1080/19420862.2021.1890411. PubMed DOI PMC

Chao M.P., Takimoto C.H., Feng D.D., McKenna K., Gip P., Liu J., Volkmer J.-P., Weissman I.L., Majeti R. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies. Front. Oncol. 2020;9:1380. doi: 10.3389/fonc.2019.01380. PubMed DOI PMC

Wang J., Asch A.S., Hamad N., Sumrow J. A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large, B.-Cell Lymphoma. ASH Publishing; Ashcroft, BC, Canada: 2020.

Jain T., Litzow M.R. No free rides: Management of toxicities of novel immunotherapies in ALL, including financial. Hematol. Am. Soc. Hematol. Educ. Program. 2018;2018:25–34. doi: 10.1182/asheducation-2018.1.25. PubMed DOI PMC

Reusch U., Duell J., Ellwanger K., Herbrecht C., Knackmuss S.H., Fucek I., Eser M., McAleese F., Molkenthin V., Gall F.L., et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. mAbs. 2015;7:584–604. doi: 10.1080/19420862.2015.1029216. PubMed DOI PMC

Yakoub-Agha I., Chabannon C., Bader P., Basak G.W., Bonig H., Ciceri F., Corbacioglu S., Duarte R.F., Einsele H., Hudecek M., et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) Haematologica. 2020;105:297–316. doi: 10.3324/haematol.2019.229781. PubMed DOI PMC

Gust J., Hay K.A., Hanafi L.-A., Li D., Myerson D., Gonzalez-Cuyar L.F., Yeung C., Liles W.C., Wurfel M., Lopez J.A., et al. Endothelial Activation and Blood—Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7:1404–1419. doi: 10.1158/2159-8290.CD-17-0698. PubMed DOI PMC

Zinzani P.L., Santoro A., Gritti G., Brice P., Barr P.M., Kuruvilla J., Cunningham D., Kline J., Johnson N.A., Mehta-Shah N., et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019;37:JCO1901492. doi: 10.1200/JCO.19.01492. PubMed DOI PMC

Mellstedt H., Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol. Immunother. CII. 2006;55:210–220. doi: 10.1007/s00262-005-0675-4. PubMed DOI PMC

Schuster S.J., Bishop M.R., Tam C.S., Waller E.K., Borchmann P., McGuirk J.P., Jaeger U., Jaglowski S., Andreadis C., Westin J.R., et al. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 2017;130:577. doi: 10.1182/blood.V130.Suppl_1.577.577. DOI

Wang M., Munoz J., Goy A., Locke F.L., Jacobson C.A., Hill B.T., Timmerman J.M., Holmes H., Jaglowski S., Flinn I.W., et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N. Engl. J. Med. 2020;382:1331–1342. doi: 10.1056/NEJMoa1914347. PubMed DOI PMC

Ramsay A.G., Johnson A.J., Lee A.M., Gorgün G., Le Dieu R., Blum W., Byrd J.C., Gribben J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 2008;118:2427–2437. doi: 10.1172/JCI35017. PubMed DOI PMC

Riches J.C., Davies J.K., McClanahan F., Fatah R., Iqbal S., Agrawal S., Ramsay A.G., Gribben J.G. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121:1612. doi: 10.1182/blood-2012-09-457531. PubMed DOI PMC